Clovis and its new ovarian cancer drug Rubraca (rucaparib). Clovis announced in February that, after it had provided an oral explanation to the CHMP at the meeting of the committee that was under way at the time, the CHMP had communicated a positive trend vote and had told the company that it intended to hold a final vote on the treatment indication at its meeting the following month. A positive opinion was duly adopted at the CHMP's March meeting and the product has since been approved. It had taken Clovis a long time to get to this stage. There had been three LoIs (and a fourth was to come), so it is perhaps not surprising the company went public with the trend vote rather than wait a month before the formal vote was taken and the result announced by the CHMP. (Also see "Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections" - Pink Sheet, 23 March, 2018.) (Also see "Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications" - Pink Sheet, 20 March, 2018.)

Companies Reveal Likely EU Review Outcomes Against EMA Advice

More from Product Reviews

More from Pink Sheet